Tag: AstraZeneca (AZN)

AI in Healthcare: Why Schrodinger (SDGR) Could Transform Drug Discovery

Posted on by The INO.com Team

Artificial intelligence (AI) is revolutionizing the pharmaceutical industry by making drug discovery faster, more efficient, and cost-effective. Traditionally, drug development is a lengthy and expensive process, often taking over a decade and costing billions of dollars. AI is changing this landscape by enabling computational modeling to predict molecular interactions, optimize drug candidates, and reduce trial-and-error experimentation.

One of the leaders in this space is Schrodinger, Inc. (SDGR), a company that has built a physics-based computational platform for drug discovery. Schrodinger’s software leverages AI and molecular simulations to accelerate the identification of promising compounds. As AI adoption in healthcare grows, Schrodinger’s technology could become an integral part of modern drug R&D. The company’s ability to integrate AI with physics-based modeling distinguishes it from other players in the space, making it a pioneer in digital-first drug discovery.

The increasing reliance on AI in pharmaceutical research is also being driven by regulatory bodies and policymakers who recognize the need for more efficient drug development. The FDA, for example, has shown interest in AI applications for drug discovery, providing a favorable environment for companies like Schrodinger. As regulatory support grows, the acceptance of AI-powered drug development could become more widespread, benefiting Schrodinger and similar companies.

Investment in AI-Driven Healthcare Solutions

The pharmaceutical sector has seen a surge in investments in AI-based solutions. According to CB Insights, funding for AI-driven drug discovery startups exceeded $3 billion in 2024 (as of 12/09/2024), up 43% from the 2023 level. Major pharmaceutical firms are increasingly partnering with AI firms to enhance their drug pipelines.

Big pharmaceutical companies such as AstraZeneca (AZN), Novartis (VVS), and Bristol-Myers Squibb (BMY) have invested heavily in AI-driven drug discovery partnerships. These investments indicate a long-term shift towards computational-first drug discovery, reducing dependency on traditional, high-cost laboratory experiments. AI is not just expediting drug discovery but also optimizing clinical trial processes, leading to better patient stratification and higher success rates in drug approvals.

The global AI in the drug discovery market is expected to grow at a CAGR of 29.7% from 2024 to 2030. The rapid expansion of this market reflects strong demand for computational approaches in drug research. With AI reducing both costs and development timelines, traditional pharmaceutical research is transitioning toward digital-first approaches. This transformation presents a significant opportunity for Schrodinger, whose platform is designed to facilitate AI-driven pharmaceutical R&D.

Schrodinger’s Platform for Computational Drug Discovery

Schrodinger combines physics-based simulations with AI and machine learning to enhance drug discovery processes. Its proprietary Free Energy Perturbation (FEP+) technology allows scientists to accurately predict the binding affinity of drug candidates, significantly improving hit-to-lead and lead optimization phases.

In Q2 2024, Schrodinger reported $35.4 million in software revenue, a 21% year-over-year increase. The company’s software revenue has grown consistently, indicating strong adoption among pharmaceutical firms. In addition to software, Schrodinger’s drug discovery partnerships generated $11.9 million in Q2 revenue, reflecting a 104% increase from the previous year. These numbers highlight the growing acceptance of AI-driven drug discovery and the company’s ability to monetize its platform through partnerships and licensing agreements.

Schrodinger is also actively developing its own drug candidates. Its proprietary therapeutics pipeline includes SGR-1505 (a MALT1 inhibitor) and SGR-2921 (a CDC7 inhibitor), both of which are expected to yield Phase 1 clinical data in 2025. The company’s ability to leverage its computational tools for in-house drug development adds another layer of potential value. Additionally, Schrodinger has received a $10 million grant from the Bill & Melinda Gates Foundation to enhance predictive toxicology tools using AI. This initiative further validates the real-world impact of the company’s platform.

Risks and Future Prospects

While Schrodinger’s AI-driven approach has significant potential, there are risks to consider. One key risk is the company’s dependence on collaborators for revenue growth. Many of its drug discovery revenues depend on milestones achieved through partnerships with pharmaceutical companies. If partners delay or cancel projects, it could impact Schrodinger’s financial performance.

Another challenge is the high cost of research and development. The company’s operating expenses increased 12% year-over-year in Q2 2024, primarily due to higher R&D investments. While this spending is essential for innovation, it also increases the company’s cash burn rate. Schrodinger’s current cash position of $381.5 million provides a financial cushion, but continuous investment in R&D means that the company will need to maintain strong revenue growth to sustain operations.

Stock volatility is another consideration. As a growth-oriented tech-healthcare stock, Schrodinger’s valuation is sensitive to market fluctuations and investor sentiment. AI-driven stocks, in particular, have experienced significant swings in valuation due to broader market conditions and changing investor risk appetites. Despite this, Schrodinger remains well-positioned in a sector that is poised for long-term expansion.

What Investors Should Consider

Schrodinger’s AI-powered platform positions it as a key player in computational drug discovery, an area poised for rapid expansion. With strong software adoption, increasing pharma partnerships, and a growing proprietary pipeline, SDGR could offer long-term value.

Short-term traders may find SDGR attractive due to its recent financial momentum. Long-term investors should consider its growth potential in AI-driven drug development, especially as the industry continues shifting toward computational approaches. Risk-tolerant biotech investors might view SDGR as a disruptive force with high upside potential, albeit with some financial uncertainties.

Given the company’s expanding AI capabilities, growing revenue streams, and industry tailwinds, Schrodinger is a stock worth watching in the evolving healthcare technology landscape. As AI continues to shape the future of drug discovery, Schrodinger’s position as an industry leader could make it a compelling choice for forward-looking investors.

The Best of the Best in Big Pharma

Posted on by The INO.com Team

Two of the world’s major listed drugmakers - AstraZeneca (AZN) and GSK (GSK) - both celebrated a strong start to 2023 and confirmed their forecasts for the rest of the year.

However, the two stocks are valued very differently by Wall Street. AstraZeneca shareholders are willing to pay 20 times forward earnings per share for 2023, while GSK’s shareholders are willing to pay a mere 10 times earnings.

These investors may be missing a huge opportunity. Last year, GSK completed its biggest restructuring in 20 years. It spun off its consumer health division Haleon (HLN), which sells over-the-counter medicines.

It is using the $8.78 billion bounty from the split to make acquisitions to fill its pipeline.

GSK’s vaccine division is the company’s star. It has developed the first ever vaccine for the common infection respiratory syncytial virus (RSV), which it believes presents a similar sized market opportunity to its shingles vaccine, which generated over $1 billion in sales in the first quarter alone. This vaccine was the first to ever be approved against RSV just a few days ago.

The company also has a leadership position in infectious diseases, which account for two-thirds of the drugs in its pipeline target.

Meanwhile, AstraZeneca has benefited from fortuitous timing, investing in oncology just as the science made great leaps forward over the past decade. The company then built on its success, so it now has a pipeline with drugs based on every current promising approach to cancer.

So, we have two very successful pharma giants. How do we pick which one to invest in? The quick and easy way to do this is to ask Magnifi to run the comparison for us. It’s as simple as asking Magnifi to “Compare AZN to GSK.”

Compare AZN to GSK

This is an example of a response using Magnifi. This image is not a recommendation or individual advice. Please see bottom disclaimer for additional information, including INO.com’s relationship with Magnifi. Continue reading "The Best of the Best in Big Pharma" →

AstraZeneca’s (AZN) Blockbuster Drug Pipeline

Posted on by The INO.com Team

Finding winners in the pharmaceutical sector is not an easy process. But it is potentially quite lucrative.

For the pharmaceutical companies themselves, the current environment for success is reminiscent of the Greek myth surrounding Sisyphus, whom the gods condemned to repeatedly roll a boulder up a hill—only to have it roll down again once he got it to the top—for all eternity.

Today’s pharmaceutical firms must use vast amounts of capital in search of a blockbuster drug, which can generate $1 billion or more in annual sales. But then, even when such a medicine is found, the benefits provided are fleeting: from the moment a drug makes it to market, the clock begins ticking on its patent exclusivity. Once this expires and generic copycats reach the market—typically within a decade or so—revenues for the original inevitably fall, and often quite rapidly.

Then, like Sisyphus, the companies climb the hill of developing blockbuster drugs again, investing anew in the whole risky and costly process of drug development.

If you are an investor in the sector, you want to focus on the companies that have drugs in their pipelines with blockbuster potential, as well as the funds necessary to propel them through several trial stages.

Since 2010, the global pharmaceutical sector has invested the equivalent of around one quarter of its revenues in drug development each year. The U.S. industry alone spent some $83 billion on R&D in 2019—when adjusted for inflation, that’s about 10 times what it spent in the 1980s!

So, which segments of the pharmaceutical industry (and which drug companies) are poised to come up with the next blockbuster drugs?

Precision Therapies

Recent advances in science are ushering in a new era of highly effective personalized medicines. So-called precision therapies are based on greater understanding of how diseases work on a molecular level. This translates to doctors being able to identify what treatments fit which patients, and why.

Precision therapies are tailored to fit specific groups of people. This means they will likely be highly effective. But can cutting-edge personalized medicines reach blockbuster drug status? The naysayers say the market size is too small…but they seem to forget that innovative drugs can command very high price tags.

Consider recent data from the drug price tracking service division of GoodRX (GDRX). It shows that, after 15 years on the market, the average drug with accelerated approval by the FDA underwent 15.4 price increases. Drugs subject to conventional approval saw 12.7 price increases in the same span of time.

Keeping an eye on the list of development-stage therapies expedited through the FDA’s approval processes can provide insight into which companies have potential blockbusters in the pipeline. Continue reading "AstraZeneca’s (AZN) Blockbuster Drug Pipeline" →